Proactiveinvestors interviews Bob Proulx on what FDA’s designation of MagSense® imaging as a “breakthrough device” means for the company and its investors:
https://youtu.be/X4HLKyIl6Zo
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance